Novo Nordisk ’ s once-weekly Type II diabetes med approved in Europe

The European Commission has approved Novo Nordisk‘s (NYSE:NVO) once-weekly semaglutide drug, Ozempic, as a treatment for adults with Type II diabetes.
The GLP-1 analogue’s label in Europe recommends that the drug is given when metformin is contraindicated or not tolerated, Novo Nordisk reported today.
Get the full story at our sister site, Drug Delivery Business News.
The post Novo Nordisk’s once-weekly Type II diabetes med approved in Europe appeared first on MassDevice.

Source: Mass Device - February 9, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Regulatory/Compliance Wall Street Beat Novo Nordisk Source Type: news